You are here

Yttrium therapy

Document

Fibrosing interstitial lung disease - Yttrium therapy Factor

Last reviewed for CCPS 16 December 2009.

Preliminary questions [40667]

40686 there is some evidence that yttrium-90 microspheres as therapy may be a factor in the development or worsening of the condition under consideration.

40994 the veteran has received yttrium-90 microspheres as therapy at some time.

40995 the veteran received yttrium-90 microspheres as therapy for primary and metastatic liver tumours.

40996the veteran received yttrium-90 microspheres as therapy for treatment of an illness or injury which is identifiable.

40999the veteran has established the causal connection between yttrium-90 microspheres as therapy and VEA service for fibrosing interstitial lung disease.

40997

for treatment of the identified illness or injury, the veteran received yttrium-90 microspheres as therapy before the clinical onset of fibrosing interstitial lung disease.

41000the veteran has established the causal connection between yttrium-90 microspheres as therapy and VEA service for the clinical onset of fibrosing interstitial lung disease.

41002the veteran has established the causal connection between yttrium-90 microspheres as therapy and operational service for the clinical onset of fibrosing interstitial lung disease.

or

41003the veteran has established the causal connection between yttrium-90 microspheres as therapy and eligible service for the clinical onset of fibrosing interstitial lung disease.

or

7334

the clinical onset of the condition under consideration occurred after the end of the veteran's last period of VEA service.

7335

the condition under consideration permanently worsened.

40998

for treatment of the identified illness or injury, the veteran received yttrium-90 microspheres as therapy before the clinical worsening of fibrosing interstitial lung disease.

41001the veteran has established the causal connection between yttrium-90 microspheres as therapy and VEA service for the clinical worsening of fibrosing interstitial lung disease.

41004the veteran has established the causal connection between yttrium-90 microspheres as therapy and operational service for the clinical worsening of fibrosing interstitial lung disease.

or

41005the veteran has established the causal connection between yttrium-90 microspheres as therapy and eligible service for the clinical worsening of fibrosing interstitial lung disease.

Clinical onset and operational service [41002]

41006the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related to operational service.

Clinical onset and eligible service [41003]

41007the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related to eligible service.

Clinical worsening and operational service [41004]

41006the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related to operational service.

41008

the clinical onset of the condition under consideration occurred prior to that part of operational service to which the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related.

Clinical worsening and eligible service [41005]

41007the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related to eligible service.

41009

the clinical onset of the condition under consideration occurred prior to that part of eligible service to which the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related.